Enpatoran
Based on 19 publication(s) in Google Scholar
Enpatoran (M5049) is an orally active and selective TLR7/8 antagonist. Enpatoran inhibits the activation of the downstream type I interferon pathway. Enpatoran is used in studies of cutaneous lupus erythematosus, systemic lupus erythematosus with cutaneous manifestations, and psoriasis.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity : 99.87%
- CAS No.: 2101938-42-3
- 화학식: C16H15F3N4
- 분자량:320.31
-
보관:
-20°C, sealed storage, away from moisture and light
* In solvent : -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture and light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
용액&용해도
- Protocol
- 순도&문서
- References
-
Help & FAQs
-
HY-139567
AfimetoranTLR7/8 Antagonist -
HY-11109
ResatorvidTLR4 Inhibitor -
HY-13740
ResiquimodTLR7/8 Agonist -
HY-100461
C29TLR2 Inhibitor -
HY-108473
CU-CPT 4aTLR3 Inhibitor -
HY-108471
CU-CPT22TLR1/TLR2 Antagonist -
HY-112667
CU-CPT-9aToll-like Receptor (TLR) Antagonist -
HY-12756A
E6446 dihydrochlorideTLR/SCD1 Inhibitor -
HY-124603
AT791TLR7/TLR9 Inhibitor -
HY-117287
DeucravacitinibTYK2 Inhibitor -
HY-139323
TLR7/8-IN-1TLR7/TLR8 Inhibitor -
HY-15601
VesatolimodTLR7 Agonist
Publications Citing Use of MedChemExpress (MCE) Enpatoran
More- Science. 2026 Feb 26;391(6788):eads4405. [Abstract]
- Immunity. 2026 Mar 26:S1074-7613(26)00083-X. [Abstract]
- J Extracell Vesicles. 2025 Jul;14(7):e70134. [Abstract]
- Adv Sci (Weinh). 2026 Jun;13(31):e14588. [Abstract]
- Biomaterials. 2026 Aug:331:124126. [Abstract]
- Cell Commun Signal. 2024 Nov 8;22(1):536. [Abstract]
- Cell Commun Signal. 2023 Aug 18;21(1):215. [Abstract]
- Acta Pharmacol Sin. 2026 Aug 24.
- Br J Pharmacol. 2024 Oct;181(19):3760-3778. [Abstract]
- J Med Chem. 2025 Dec 15;68(24):26030–26048.
- J Autoimmun. 2024 May:145:103189. [Abstract]
- Int Immunopharmacol. 2025 Jun 17:158:114804. [Abstract]
- J Periodontal Res. 2025 Feb 25. [Abstract]
- J Innate Immun. 2023;15(1):517-530. [Abstract]
- Mol Immunol. 2026 Feb:190:101-109. [Abstract]
- Patent. US20250312471A1.
- Biomed Pharmacother. 2025 Sep 17:192:118569. [Abstract]
- bioRxiv. 2024 July 25.
- bioRxiv. 2024 Jul 15:2024.07.15.603540. [Abstract]
Customer Validation & Images
-
ELISA
-
In Vivo Efficacy Study
-
RT-PCR
-
Histological Imaging/Staining
-
WB
Biological Activity
제품 설명
IC50 & Target
[2]|
TLR8 |
TLR7 |
In Vitro
Enpatoran (1 μM; 1 h pretreatment before pso-miR stimulation) potently suppresses pso-miR-triggered NK cell degranulation (CD107a surface expression) in human PBMCs[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BXSB-Yaa mice (Male, 7 to 8 weeks old, sourced from Jackson Laboratories)[3]
-
Dosage:0.1, 1, 10 mg/kg
-
Administration:p.o.; once per day; 14 weeks
-
Result:Improved survival of BXSB-Yaa mice.
Reduced kidney disease as evidenced by decreased proteinuria (lower urinary albumin-to-creatinine ratio).
Significantly reduced levels of both DNA-containing autoantibodies (anti-dsDNA, anti-histone) and RNA-binding protein autoantibodies (anti-RiboP, anti-SmRNP), with 10 mg/kg doses reducing autoantibody titers below pre-treatment baseline levels.
Significantly reduced IFN gene signature scores calculated from a panel of 10 IFN-regulated disease-related genes, and downregulated expression of myeloid and granulocyte marker genes (CLEC4E, TLR8, FCER1G, LILRA5) as well as TLR7.
Chemical Information
-
CAS No. 2101938-42-3
-
Appearance Solid
-
분자량 320.31
-
화학식 C16H15F3N4
-
Color Light yellow to yellow
-
SMILES
N#CC(C=C1)=C(N=CC=C2)C2=C1N3C[C@@H](C(F)(F)F)C[C@@H](N)C3
-
Synonyms
M5049
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
-20°C, sealed storage, away from moisture and light
* In solvent : -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture and light)
Publications (19)
-
Journal Impact Factor
-
Most Recent
-
Science
2026 Feb 26;391(6788):eads4405. PMID: 41747053 -
Immunity
p16High-expressing immune cells control disease tolerance as a defense and health span-extending strategy. [Abstract]2026 Mar 26:S1074-7613(26)00083-X. PMID: 41895292 -
J Extracell Vesicles
Extracellular Vesicles Derived From Streptococcus anginosus Aggravate Lupus Nephritis by Triggering TLR2-MyD88-NF-κB Signalling in NK Cells. [Abstract]2025 Jul;14(7):e70134. PMID: 40673809 -
Adv Sci (Weinh)
Improved Systemic Immunochemotherapy Employing an Oxaliplatin-TLR7/8 Agonist Prodrug Strategy. [Abstract]2026 Jun;13(31):e14588. PMID: 41969225 -
Biomaterials
Conjugated polymer intrachain donor-acceptor reconfiguration-tailored off-on NIR-II photoacoustic probes with ultralow background for high-fidelity imaging of immunotherapy-associated macrophage reprogramming. [Abstract]2026 Aug:331:124126. PMID: 41830766 -
Cell Commun Signal
Cell damage shifts the microRNA content of small extracellular vesicles into a Toll-like receptor 7-activating cargo capable to propagate inflammation and immunity. [Abstract]2024 Nov 8;22(1):536. PMID: 39516877
Enpatoran purchased from MedChemExpress. Usage Cited in: Cell Commun Signal. 2024 Nov 8;22(1):536. [Abstract]
pDCs were pretreated or not with Enpatoran (Enp, 1 µM) for 1 h and then stimulated with miR203a for 24 h. IFN-α secretion was evaluated by ELISA.
-
Cell Commun Signal
TLR7 activation by miR-21 promotes renal fibrosis by activating the pro-inflammatory signaling pathway in tubule epithelial cells. [Abstract]2023 Aug 18;21(1):215. PMID: 37596656
Enpatoran purchased from MedChemExpress. Usage Cited in: Cell Commun Signal. 2023 Aug 18;21(1):215. [Abstract]
M5049 (0.3 mg/kg; oral administration). Serum BUN levels of folic acid-treated mice with or without M5049 administration.
Enpatoran purchased from MedChemExpress. Usage Cited in: Cell Commun Signal. 2023 Aug 18;21(1):215. [Abstract]
M5049 (0.3 mg/kg; oral administration). Relative mRNA levels of kidney damage-related genes (Havcr1 and Lcn2) in the kidney of folic acid-treated mice with or without M5049 administration.
Enpatoran purchased from MedChemExpress. Usage Cited in: Cell Commun Signal. 2023 Aug 18;21(1):215. [Abstract]
M5049 (0.3 mg/kg; oral administration). Relative mRNA levels of kidney damage-related genes (Havcr1 and Lcn2) in the kidney of folic acid-treated mice with or without M5049 administration.
Enpatoran purchased from MedChemExpress. Usage Cited in: Cell Commun Signal. 2023 Aug 18;21(1):215. [Abstract]
M5049 (0.3 mg/kg; oral administration). Protein levels of p65, p-p65, CD3, and CD68 in the kidneys were determined via western blotting. α-tubulin was used as a loading control.
Enpatoran purchased from MedChemExpress. Usage Cited in: Cell Commun Signal. 2023 Aug 18;21(1):215. [Abstract]
M5049 (0.3 mg/kg; oral administration). Representative IHC images of p-p65 in the kidneys.
-
-
Br J Pharmacol
2024 Oct;181(19):3760-3778. PMID: 38872396 -
-
J Autoimmun
Extracellular microRNAs induce dendritic cell-dependent joint inflammation and potentiate osteoclast differentiation via TLR7/8 engagement. [Abstract]2024 May:145:103189. PMID: 38442677 -
Int Immunopharmacol
Elevated transferrin receptor 1 promoting B-cell autoimmunity in systemic lupus erythematosus. [Abstract]2025 Jun 17:158:114804. PMID: 40373595 -
J Periodontal Res
Toll-Like Receptor 7 Promotes Periodontal Inflammation and Alveolar Bone Resorption Through the NF-κB Signaling Pathway. [Abstract]2025 Feb 25. PMID: 40007244 -
J Innate Immun
TLR7 activation in M-CSF-dependent monocyte-derived human macrophages potentiates inflammatory responses and prompts neutrophil recruitment. [Abstract]2023;15(1):517-530. PMID: 37040733 -
Mol Immunol
2026 Feb:190:101-109. PMID: 41564652 -
-
Biomed Pharmacother
Baicalin attenuates acetaminophen-induced acute liver injury through inhibiting TLR2-dependent neutrophil extracellular trap formation. [Abstract]2025 Sep 17:192:118569. PMID: 40967078 -
-
bioRxiv
p16High immune cell - controlled disease tolerance as a broad defense and healthspan extending strategy. [Abstract]2024 Jul 15:2024.07.15.603540. PMID: 39026790
용액&용해도
In Vitro:
DMSO : 100 mg/mL (312.20 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Ethanol : 100 mg/mL (312.20 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture and light). When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture and light). When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.44 mg/mL (7.62 mM); Clear solution
This protocol yields a clear solution of ≥ 2.44 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (24.4 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.44 mg/mL (7.62 mM); Clear solution
This protocol yields a clear solution of ≥ 2.44 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (24.4 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture and light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
순도&문서
-
Data Sheet (278 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture and light). When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO / Ethanol | 1 mM | 3.1220 mL | 15.6099 mL | 31.2198 mL | 78.0494 mL |
| 5 mM | 0.6244 mL | 3.1220 mL | 6.2440 mL | 15.6099 mL | |
| 10 mM | 0.3122 mL | 1.5610 mL | 3.1220 mL | 7.8049 mL | |
| 15 mM | 0.2081 mL | 1.0407 mL | 2.0813 mL | 5.2033 mL | |
| 20 mM | 0.1561 mL | 0.7805 mL | 1.5610 mL | 3.9025 mL | |
| 25 mM | 0.1249 mL | 0.6244 mL | 1.2488 mL | 3.1220 mL | |
| 30 mM | 0.1041 mL | 0.5203 mL | 1.0407 mL | 2.6016 mL | |
| 40 mM | 0.0780 mL | 0.3902 mL | 0.7805 mL | 1.9512 mL | |
| 50 mM | 0.0624 mL | 0.3122 mL | 0.6244 mL | 1.5610 mL | |
| 60 mM | 0.0520 mL | 0.2602 mL | 0.5203 mL | 1.3008 mL | |
| 80 mM | 0.0390 mL | 0.1951 mL | 0.3902 mL | 0.9756 mL | |
| 100 mM | 0.0312 mL | 0.1561 mL | 0.3122 mL | 0.7805 mL |
Enpatoran Related Classifications
HY-134581 Related Classifications
Powered by Bioz